



Transfecting Plasmid DNA into MDA-MB-231-ATCC Cells Using Lipofectamine™ LTX Reagent

Terms and Conditions of Use

Invitrogen Corporation ("Invitrogen") grants to you, its customer, a non-exclusive, non-transferable license to access the Invitrogen transfection protocol applicable to Invitrogen products, as set forth below (the "Protocol"). You acknowledge that the Protocol is protected by copyright. All rights not specifically granted to you are expressly reserved to Invitrogen. You may use the Protocol for personal, educational, or scientific research or professional use, but in no case for a fee. You may not remove, obscure or modify any copyright or proprietary notices, author attribution or any disclaimer contained in the Protocol.

INVITROGEN PROVIDES THE PROTOCOL "AS IS", WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF TITLE, OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT; YOUR USE OF THE PROTOCOL IS AT YOUR OWN RISK; NEITHER INVITROGEN NOR ITS AFFILIATES, EMPLOYEES, OFFICERS OR DIRECTORS SHALL BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING OUT OF THIS LICENSE OR ANY USE OF THE PROTOCOL. Some jurisdictions do not allow the exclusion or limitation of liability for certain damages, so the above limitation may not apply to you to the extent prohibited by such local laws; if so, then Invitrogen's liability for damages hereunder shall not exceed an amount equal to the amounts paid by you hereunder, or one hundred dollars (\$100.00), whichever is less.

Confidentiality

You acknowledge the Protocol is Invitrogen's confidential information and constitutes Invitrogen's proprietary and valuable trade secrets. You agree to take reasonable care to protect the Protocol from disclosure to third parties, except as may be expressly authorized by Invitrogen.

Introduction

Lipofectamine LTX™ Reagent is a proprietary, animal-origin free formulation for the transfection of DNA into eukaryotic cells with low cytotoxicity. This reference provides a recommended procedure to transfect plasmid DNA into MDA-MB-231, human breast adenocarcinoma cells (ATCC No. HTB-26) using Lipofectamine LTX™ Reagent.

Important Guidelines for Transfection

Follow these important guidelines when transfecting MDA-MB-231 cells using Lipofectamine LTX™ Reagent:

- Maintain the same seeding conditions between experiments. Use low-passage cells; make sure cells are healthy and greater than 90% viable before transfection.
- Transfection can be performed both in the presence or absence of serum. Test serum-free media for compatibility with Lipofectamine LTX™ Reagent.
- We recommend Opti-MEM® I Reduced Serum Medium (Cat. No. 31985-070) to dilute the DNA Lipofectamine LTX™ Reagent before complexing.
- Using PLUS™ Reagent (Cat. No. 11514-015) enhances transfection performance in MDA-MB-231 Cells
- Visit www.invitrogen.com/genedelivery or contact Technical Services for other specialized transfection protocols.
- Lipofectamine LTX™ Reagent performs well with vector-based RNAi experiments. For siRNA and Stealth RNAi transfections, we recommend Lipofectamine RNAiMAX. Go to www.invitrogen.com/RNAi or contact Technical Service for more information.

Materials Needed

Have the following reagents on-hand before beginning:

- MDA-MB-231 cells maintained in Dulbecco's Modified Eagle Medium (DMEM) (Cat. No. 11960-044) supplemented with 4 mM L-Glutamine (Cat. No. 25030-081), 10% fetal bovine serum (Cat. No. 16000-044). Grow cells at 37° C with 5% CO₂.
- Plasmid DNA of interest.
- Lipofectamine LTX™ Reagent (store at +4°C until ready to use)
- Opti-MEM® I Reduced Serum Media
- Appropriate tissue culture plates and supplies

Transfecting MDA-MB-231 Cells

Use this procedure to transfect plasmid DNA into MDA-MB-231 cells in a 24-well format (for other formats, see Scaling Up or Down Transfections, below). All amounts and volumes are given on a per well basis.

1. The day before transfection, trypsinize and count the cells. Plate 1.25×10^5 cells per well in 0.5 ml of complete growth medium. Cell density should be 50-80% confluent on the day of transfection.
2. (Optional) The day of transfection, remove growth medium from cells and replace with 0.5 ml of complete growth medium.
3. For each well of cells to be transfected, dilute 0.5 µg of DNA in 100 µl of Opti-MEM® I Reduced Serum Media without serum.
4. If using PLUS™ Reagent: Mix PLUS™ Reagent gently before use, then add 0.5 µl PLUS™ Reagent (a 1:1 ratio to DNA) directly to the diluted DNA. Mix gently and incubate 5-15 minutes at room temperature.
5. For each well of cells, add 1.25-2.25 µl of Lipofectamine LTX™ Reagent into the above diluted Opti-MEM®:DNA solution, mix gently and incubate 30 minutes at room temperature to form DNA- Lipofectamine LTX™ Reagent complexes.
6. After 30 minute incubation, add 100 µl of the DNA- Lipofectamine LTX™ Reagent complexes directly to each well containing cells and mix gently by rocking the plate back and forth.
7. Complexes do not have to be removed following transfection. Incubate the cells at 37°C in a CO₂ incubator for 18-24 hours post-transfection before assaying for transgene expression.

Scaling Up or Down Transfections

Culture Vessel	Surface Area per well	Volume Plating Medium	Cells per well	Volume Dilution Medium	DNA	Lipofectamine LTX™ Reagent	PLUS™ Reagent
96-well	0.3 cm ²	100 µl	2.5×10^4	20 µl	100 ng	0.25 – 0.45 µl	0.1 µl
48-well	1 cm ²	200 µl	5×10^4	40 µl	200 ng	0.5 – 0.9 µl	0.2 µl
24-well	2 cm ²	500 µl	1.25×10^5	100 µl	500 ng	1.25 – 2.25 µl	0.5 µl
12-well	4 cm ²	1 ml	2.5×10^5	200 µl	1 µg	2.5 – 4.5 µl	1.0 µl
6-well	10 cm ²	2 ml	6.25×10^5	500 µl	2.5 µg	6.25 – 11.25 µl	2.5 µl

Purchaser Notification

This product is covered by Limited Use Label License No. 5: Invitrogen Technology (see the Invitrogen catalog or our web-site, www.invitrogen.com). By the use of this product you accept the terms and conditions of the applicable Limited Use Label License.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

©2006 Invitrogen Corporation. All rights reserved.